Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming ...
Read moreDetails(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming ...
Read moreDetails
